Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

Oregon study finds no clear link between mRNA vaccines and sudden cardiac deaths in young people

Study in Oregon finds no definitive link between mRNA COVID-19 vaccines and sudden cardiac deaths among residents aged 16-30, emphasizing vaccine safety amidst ongoing public

April 16, 2024

Antihistamines offer new hope for erythropoietic protoporphyria-related liver disease

Chlorcyclizine shows promise in reducing protoporphyrin-IX accumulation and liver damage in erythropoietic protoporphyria, targeting histamine pathways.

January 20, 2025

‘We beat big pharma’: Biden applauds IRA, calls for expansion of Medicare negotiations

President Joe Biden renewed his proposal to expand drug price negotiations under the Inflation Reduction Act on Wednesday, arguing that “we should be more aggressive.”

April 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.